Clinical Trial: 3'-Deoxy-3'-[18F] Fluorothymidine PET Imaging in Patients With Cancer
Study Status: Recruiting
Recruit Status: Recruiting
Study Type: Interventional
Official Title: Use of [F-18] FLT for Imaging With Positron Emission Tomography (PET)
Brief Summary:
RATIONALE: Diagnostic procedures, such as 3'-deoxy-3'-[18F] fluorothymidine (FLT) PET imaging, may help find and diagnose cancer. It may also help doctors predict a patient's response to treatment and help plan the best treatment.
PURPOSE: This phase I trial is studying FLT PET imaging in patients with cancer.
Detailed Summary:
OBJECTIVES:
Primary
- Evaluate the use of 3'-deoxy-3'-[18F] fluorothymidine (FLT) positron emission tomography (PET) imaging to measure tumor proliferation and the DNA synthetic pathway (thymidine kinase levels) in patients with cancer.
Secondary
- Determine the efficacy of FLT PET imaging in detecting lesions and estimating response to treatment.
OUTLINE: Patients undergo up to four 3'-deoxy-3'-[18F] fluorothymidine positron emission tomography imaging procedures.
Sponsor: Barbara Ann Karmanos Cancer Institute
Current Primary Outcome:
- Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs [ Time Frame: at time of PET or CT PET Scan ]
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values [ Time Frame: before and after therapy ]
Original Primary Outcome:
- Measurement of the uptake and retention of 3'-deoxy-3'-[18F] fluorothymidine (FLT) in tumors and normal organs
- Changes in thymidine kinase, thymidylate synthase, and standardized uptake values before and after therapy
Current Secondary Outcome: FLT PET response rate [ Time Frame: up to 2 hours during PET scan ]
Original Secondary Outcome: FLT PET response rate
Information By: Barbara Ann Karmanos Cancer Institute
Dates:
Date Received: July 7, 2009
Date Started: September 2009
Date Completion: September 2018
Last Updated: March 29, 2017
Last Verified: March 2017
